Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03418545 · ClinicalTrials.gov registry record · Phase 3
A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing
A Phase 3 study, sponsored by Allergan.
- Completed
- Registry status
- Phase 3
- Development phase
- 163
- Enrollment target
NCT03418545 is a Phase 3 study that has completed, run by Allergan. The registered enrollment target is 163 participants.
The verdict
NCT03418545, a Phase 3 study, has completed, sponsored by Allergan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 163 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM® VOLBELLA™ XC in adult participants seeking correction of hollowing of the tear troughs.
Interventions
- DEVICE JUVÉDERM VOLBELLA® XC injectable gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2018-01-26 |
| Est. Completion | 2019-08-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03418545
The ClinicalTrials.gov registry entry for NCT03418545 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which JUVÉDERM VOLBELLA® XC injectable gel is the first listed.
NCT03418545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03418545 about?
NCT03418545 is a clinical study titled "A Safety and Effectiveness of VOLBELLA XC Hyaluronic Acid (HA) Injectable Gel to Correct Infraorbital Hollowing". The objective of this study is to evaluate the safety and effectiveness of JUVÉDERM® VOLBELLA™ XC in adult participants seeking correction of hollowing of the tear troughs.
What is the current status of trial NCT03418545?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 163 participants. The study started on 2018-01-26. Estimated completion is 2019-08-22.
What interventions are being tested in trial NCT03418545?
The interventions under investigation include: JUVÉDERM VOLBELLA® XC injectable gel (DEVICE).
Who is sponsoring clinical trial NCT03418545?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.